Literature DB >> 19289627

Socioeconomic differences in patient survival are increasing for acute myeloid leukemia and multiple myeloma in sweden.

Sigurdur Yngvi Kristinsson1, Asa Rangert Derolf, Gustaf Edgren, Paul W Dickman, Magnus Björkholm.   

Abstract

PURPOSE: An association between socioeconomic status (SES) and survival in acute myeloid leukemia (AML) and multiple myeloma (MM) has not been established in developed countries. We assessed the impact of SES on survival in two large population-based cohorts of AML and MM patients diagnosed in Sweden 1973 to 2005. PATIENTS AND METHODS: The relative risk of death (all cause and cause specific) in relation to SES was estimated using Cox's proportional hazards regression. We also conducted analyses stratified by calendar periods (1973 to 1979, 1980 to 1989, 1990 to 1999, and 2000 to 2005).
RESULTS: We identified a total of 9,165 and 14,744 patients with AML and MM, respectively. Overall, higher white-collar workers had a lower mortality than other SES groups for both AML (P = .005) and MM (P < .005). In AML patients, a consistently higher overall mortality was observed in blue-collar workers compared with higher white-collar workers in the last three periods (hazard ratio [HR], 1.26; 95% CI, 1.05 to 1.51; HR, 1.23; 95% CI, 1.05 to 1.45; HR, 1.28; 95% CI, 1.04 to 1.57, respectively). In MM, no difference was observed in the first two calendar periods. However, in 1990 to 1999, self-employed (HR, 1.18; 95% CI, 1.02 to 1.37), blue-collar workers (HR, 1.18; 95% CI, 1.04 to 1.32), and retired (HR, 1.45; 95% CI, 1.16 to 1.80) had a higher mortality compared to higher white-collar workers. In 2000 to 2005, blue-collar workers had a higher mortality (HR, 1.31; 95% CI, 1.07 to 1.60) compared with higher white-collar workers.
CONCLUSION: SES was significantly associated with survival in both AML and MM. Most conspicuously, a lower mortality was observed among the highest SES group during more recent calendar periods. Differences in management, comorbidity, and lifestyle, are likely factors to explain these findings.

Entities:  

Mesh:

Year:  2009        PMID: 19289627     DOI: 10.1200/JCO.2008.18.2006

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  19 in total

Review 1.  Second malignancies after multiple myeloma: from 1960s to 2010s.

Authors:  Anish Thomas; Sham Mailankody; Neha Korde; Sigurdur Y Kristinsson; Ingemar Turesson; Ola Landgren
Journal:  Blood       Date:  2012-02-06       Impact factor: 22.113

2.  Aging and malignant hemopathies.

Authors:  Dominique Bron; Lionel Ades; Tamas Fulop; Valentin Goede
Journal:  Haematologica       Date:  2015-05       Impact factor: 9.941

Review 3.  Equal Treatment and Outcomes for Everyone with Multiple Myeloma: Are We There Yet?

Authors:  Sikander Ailawadhi; Kirtipal Bhatia; Sonikpreet Aulakh; Zahara Meghji; Asher Chanan-Khan
Journal:  Curr Hematol Malig Rep       Date:  2017-08       Impact factor: 3.952

4.  Parental longevity and survival among patients with multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study.

Authors:  Ingigerður S Sverrisdóttir; Sigrún H Lund; Ingemar Turesson; Magnus Björkholm; Lynn R Goldin; Ola Landgren; Sigurður Y Kristinsson
Journal:  Br J Haematol       Date:  2019-03-24       Impact factor: 6.998

5.  Are different groups of cancer patients offered rehabilitation to the same extent? A report from the population-based study "The Cancer Patient's World".

Authors:  Lone Ross; Morten Aagaard Petersen; Anna Thit Johnsen; Louise Hyldborg Lundstrøm; Mogens Groenvold
Journal:  Support Care Cancer       Date:  2011-05-21       Impact factor: 3.603

6.  Early mortality and complications in hospitalized adult Californians with acute myeloid leukaemia.

Authors:  Gwendolyn Ho; Brian A Jonas; Qian Li; Ann Brunson; Ted Wun; Theresa H M Keegan
Journal:  Br J Haematol       Date:  2017-04-17       Impact factor: 6.998

7.  Socioeconomic status is independently associated with overall survival in patients with multiple myeloma.

Authors:  Mark A Fiala; Joseph D Finney; Jingxia Liu; Keith E Stockerl-Goldstein; Michael H Tomasson; Ravi Vij; Tanya M Wildes
Journal:  Leuk Lymphoma       Date:  2015-03-08

8.  Outcome of acute myeloid leukemia patients with hyperleukocytosis in Brazil.

Authors:  L C O Oliveira; L G M Romano; B P A Prado-Junior; D T Covas; E M Rego; G C De Santis
Journal:  Med Oncol       Date:  2009-11-25       Impact factor: 3.064

Review 9.  [Cancer and life style: What really helps?].

Authors:  U Seifart
Journal:  Internist (Berl)       Date:  2016-01       Impact factor: 0.743

10.  Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Institute-designated cancer centers in California.

Authors:  Gwendolyn Ho; Ted Wun; Lori Muffly; Qian Li; Ann Brunson; Aaron S Rosenberg; Brian A Jonas; Theresa H M Keegan
Journal:  Cancer       Date:  2018-02-16       Impact factor: 6.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.